首页> Pediatric hematology and oncology> Management of growth failure and growth hormone deficiency after pediatric allogeneic HSCT: Endocrinologists are of importance for further guidelines and studies.

Management of growth failure and growth hormone deficiency after pediatric allogeneic HSCT: Endocrinologists are of importance for further guidelines and studies.

导出 LinkOut

翻译打印收藏纠错

第一作者： A,Lawitschka

第一单位： St. Anna Children's Hospital, Vienna Medical University, Vienna, Austria.

作者： A,Lawitschka ^[1] ; P,Schwarze ^[2] ; A,Rovelli ^[3] ; M,Badoglio ^[4] ; G,Socie ^[5] ; A,Tichelli ^[6] ; D,Bauer ^[1] ; A,Rovo ^[7] ; G,Basak ^[8] ; H,Schoemans ^[9] ; C,Peters ^[1] ; N,Salooja ^[10]

作者单位： St. Anna Children's Hospital, Vienna Medical University, Vienna, Austria. ^[1] Department of General Pediatrics, Hematology/Oncology, University Children's Hospital, Tuebingen, Germany. ^[2] MBBM Foundation, Bone Marrow Transplantation Unit, Pediatric Department of Milano-Bicocca University, Monza, Italy. ^[3] Department of Haematology, EBMT Paris Study Office, Saint Antoine Hospital, Paris, France. ^[4] Department of Hematology, Hôpital Saint Louis, Paris, France. ^[5] Department for Haematology, University Hospital Basel, Basel, Switzerland. ^[6] Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern. ^[7] Department of Hematology, Oncology, and Internal Diseases, Medical University of Warsaw, Warsaw, Poland. ^[8] Department of Hematology, University Hospital Leuven and KU Leuven, Leuven, Belgium. ^[9] Centre for Haematology, Imperial College London, London, UK. ^[10]

关键词 Pediatric endocrinology endocrinology growth hormone treatment late effects of cancer treatment long term survival